Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
January 7, 2022•Conference Begins on January 10, 2022RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive...
-
January 7, 2022•New details of clinical trial for BriLife™ to be discussed during company update presentation at the H.C. Wainwright BioConnect Virtual Conference
RADNOR, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive...
-
January 5, 2022- Requested indication focuses on patients whose respiratory failure has progressed despite treatment with Remdesivir or other approved therapies
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) for the use of ZYESAMI®...
-
January 3, 2022- Invention by NRx scientists provides a path to long-term patent protection for ZYESAMI® (aviptadil)
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a provisional composition of matter patent application with the US Patent and Trademark Office entitled "Stable, Buffer-free...
-
December 28, 2021- Breakthrough Therapy Designation request focused on patients whose respiratory failure has progressed despite treatment with Remdesivir
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration (FDA) focused on patients with...
Click here to view our corporate presentation or on the image below
 |
